13th of July, 2017
Medicinal Product Regulation & Product Liability in Egypt: Overview
Keywords: Infrastructure & Projects, Retail & Consumer Goods, Commercial
Sharkawy & Sarhan team published in June 2017 an article on “Medicinal Product Regulation and Product Liability in Egypt: overview” in collaboration with Thomson Reuters, as part of its Life Sciences Global Guide 2017/2018.
The publication provides an overview of pharmaceutical business regulations in Egypt. Such overview covers key aspects that are important to know by stakeholders interested in the sector such as:
(i) registration of pharmaceutical products,
(ii) pricing and public funding of healthcare services,
(iii) clinical trials,
(iv) manufacturing,
(v) marketing and promotional programs,
(vi) parallel importation and
(vii) product liability.
The publication provides an overview of pharmaceutical business regulations in Egypt. Such overview covers key aspects that are important to know by stakeholders interested in the sector such as:
(i) registration of pharmaceutical products,
(ii) pricing and public funding of healthcare services,
(iii) clinical trials,
(iv) manufacturing,
(v) marketing and promotional programs,
(vi) parallel importation and
(vii) product liability.
Medicinal Product Regulation & Product Liability in Egypt: Overview
13 July, 2017
Keywords:Infrastructure & Projects, Retail & Consumer Goods, Commercial
Sharkawy & Sarhan team published in June 2017 an article on “Medicinal Product Regulation and Product Liability in Egypt: overview” in collaboration with Thomson Reuters, as part of its Life Sciences Global Guide 2017/2018.
The publication provides an overview of pharmaceutical business regulations in Egypt. Such overview covers key aspects that are important to know by stakeholders interested in the sector such as:
(i) registration of pharmaceutical products,
(ii) pricing and public funding of healthcare services,
(iii) clinical trials,
(iv) manufacturing,
(v) marketing and promotional programs,
(vi) parallel importation and
(vii) product liability.
The publication provides an overview of pharmaceutical business regulations in Egypt. Such overview covers key aspects that are important to know by stakeholders interested in the sector such as:
(i) registration of pharmaceutical products,
(ii) pricing and public funding of healthcare services,
(iii) clinical trials,
(iv) manufacturing,
(v) marketing and promotional programs,
(vi) parallel importation and
(vii) product liability.
Key Contacts
Ahmed El Sharkawy
PARTNER
Key Contacts
Ahmed El Sharkawy
PARTNER
Insights
Sharkawy & Sarhan IFLR1000 Middle East Rankings 2024
Sharkawy & Sarhan 2024 Promotions!
Sharkawy & Sarhan is shortlisted by Chambers & Partners for two Awards
Disclaimer
The information included in this publication/client alert is not legal advice or any other advice. Publications and client alerts on this site are current as of their date of publication and do not necessarily reflect the present law or regulations. Please feel free to contact us should you need any legal advice related to the publication/client alert. Sharkawy & Sarhan (the “Firm”) will not be held liable for any compensatory, special, direct, incidental, indirect, or consequential damages, exemplary damages or any damages whatsoever arising out of or in connection with the use of the data, information or material included in this publication/client alert. This publication/client alert may contain links to third-party websites that are not controlled by the Firm. These third-party links are made available to you as a convenience and you agree to use these links at your own risk. Please be aware that the Firm is not responsible for the content or services offered by and of third-party websites, links as included in the Newsletter nor are we responsible for the privacy policy or practices of third-party websites links included therein.
Authorization of Use
The data, information, and material included in this publication/client alert are solely owned by the Firm. All rights related are reserved under the laws of the Arab Republic of Egypt. No part of this publication/client alert can be redistributed, copied, or reproduced without the prior written consent of the Firm.